Navigation Links
SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Date:12/17/2007

DUBLIN, Calif., December 17 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) today announced that investigators have dosed the first patient in a multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470 in combination with several standard of care chemotherapy regimens, including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel, topotecan, and erlotinib. The trial is expected to enroll up to 105 patients at five study centers.

The Phase 1b trial is an open label, dose-escalation study designed to assess the safety and tolerability of MP470 in combination with these standard of care chemotherapy regimens, and to define the dose of MP470 to advance into Phase 2 combination studies. Additionally, the Company will assess pharmacokinetic and biomarker data from the study. The trial is open to chemotherapy nave or treatment experienced patients with a variety of solid tumors irrespective of previous lines of therapy.

"MP470 shows significant preclinical synergy with all of these well established chemotherapy agents. Its preclinical toxicology profile, as well as preliminary safety data from our ongoing Phase 1 trial suggests it will be safe to combine it with these regimens," said Dr. Gregory Berk, Chief Medical Officer of SuperGen. "In preclinical models, MP470 also suppresses Rad51, a protein that plays a key role in the mechanism of resistance to these treatments. We believe this offers the potential for MP470 to improve on the efficacy of these therapies. The multi-arm, Phase 1b design allows us to accelerate the clinical development of MP470 which will expedite the timeline to our Phase 2 program."

About MP470

MP470 is
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
2. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...s treated at the initial dose in an ongoing Phase ...d decline after three days , , Conference Call ...ewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc....e first cohort of an ongoing Phase Ib clinical tri...cleoside polymerase inhibitor. ANA598 was very we...
(Date:1/7/2009)..., Tenn., Jan. 7 Scienti...ct a high likelihood of relapse in children with a...searchers caution that further research is needed ...1 or IKAROS, lead to leukemia relapse, the find...agnostic tests to assess the risk of treatment fai...
(Date:1/7/2009)...CK, Md., Jan. 7 ImQuest Life Scien...n IND application to the Food and Drug Administrat...ad pyrimidinedione HIV inhibitor IQP-0410. ImQuest...he first quarter of 2009. IQP-0410 is a novel smal...s a nonnucleoside reverse transcriptase inhibitor ...
(Date:1/7/2009)..., Jan. 7 Tiantan Puhua Hospital St... the worldwide leader in using stem cells to effec...ay six new globally experienced additions to its m...d the hospital,s treatment capabilities for growin...six senior doctors include the distinguished Dr. J...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 1Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 2Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 3Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 4Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 5Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 6Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 7Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 8The American Journal of Nursing honors Jean and Ric Edelman 28137 1The American Journal of Nursing honors Jean and Ric Edelman 28137 2The American Journal of Nursing honors Jean and Ric Edelman 28137 3Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 1Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 2Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 3Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 4mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 1mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 2mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 3mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 4mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 5mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 6
... protein,protects human pancreatic cancer cells fr... of the body,s natural defenses against,out-of-con... Texas,M. D. Anderson Cancer Center report in the ...otein tissue transglutaminase, known by the abbrev...rs at M. D. Anderson and,elsewhere to be overexpre...
...cal studies have,shown (1) similar rates of neurol... patients being treated with Tamiflu compared to,t...urthermore,recent data derived from US health ins...00 influenza patients treated with Tamiflu,and ove...ve shown,that the Tamiflu treated patients showed ...
Other Medicine Technology:Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3New Data from the US and Japan Support: No Established Causal Link,Between Neuropsychiatric Symptoms and Treatment with Tamiflu US,Databases Indicate Psychiatric Symptoms Lower in Influenza Patients,Taking Tamiflu Versus Those Not Taking Tamiflu 2New Data from the US and Japan Support: No Established Causal Link,Between Neuropsychiatric Symptoms and Treatment with Tamiflu US,Databases Indicate Psychiatric Symptoms Lower in Influenza Patients,Taking Tamiflu Versus Those Not Taking Tamiflu 3New Data from the US and Japan Support: No Established Causal Link,Between Neuropsychiatric Symptoms and Treatment with Tamiflu US,Databases Indicate Psychiatric Symptoms Lower in Influenza Patients,Taking Tamiflu Versus Those Not Taking Tamiflu 4
(Date:1/8/2009)..., Md., Jan. 8 Hanger Or...announce that throughout the fourth quarter of 200... Center, Rocky Mountain Orthotic-Prosthetics Cente...nc., First Coast Orthotics & Prosthetics, and ...uisitions add patient care centers to existing mar...
(Date:1/8/2009)...FRANCISCO, Jan. 8 Mediva... David Hung, M.D., president and chief,executive ...an Healthcare,Conference on Wednesday, January 14...ancis Hotel in San Francisco. , Dr. Hung wi...cal,development programs for Dimebon for Alzheime...
(Date:1/8/2009)...E, Md., Jan. 8 A new ed...ice and guidance on drugs, biological products and...search and Quality,s Centers for Education and Res...ed network of more than a dozen leading research c...Advisory Information Network ( CHAIN ) http://www...
(Date:1/8/2009)...ne Promoted to Principal. Christine Siu and Jason...NNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn., Jan...., a health care venture capital firm that invests ...today announced the promotion of three members of ... to Principal. Christine Siu and Jason Brown have...
Breaking Medicine News(10 mins):Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2
...be treated by using state-of-the-art gene therapy ...field have developed a way of blasting DNA into ce...in caused when the heart is starved of blood due t...t may precede a heart attack. In many cases this i...
...f inheritable genes to enable people to produce mo...ttitudes to family relationships and on being huma...spiring parents with inheritable diseases hold out...offers them the possibility of avoiding passing di...
...p forward in dissecting the pathways and mechanism...hers of Yale University have seen a break through ...e adult onset Type II Diabetes mellitus. The...g a gene that produces the enzyme called Akt2 or /...
...rchers, patients suffering from Angina may have so...rapy or doses of antibiotics. Angina, a common car...all over the world, is severe chest pain caused by...od to the heart during// physical activity. Curren...
Other Medicine News:Health News:Perfect babies boon or a bane? 2Health News:Breakthrough in Type II Diabetes 2Health News:Antibiotic, Gene Therapy Help Treat Angina 2Health News:Antibiotic, Gene Therapy Help Treat Angina 3
...he first objective measurement for CHF. Blood test...diac hormone produced by the heart ventricles in r...re overload. Excellent hormonal marker of ventricu... BNP Test provides meaningful diagnostic informati...
...alvage System offers five different products for l...ese components are cobalt-chrome, ultra high molec...AN products are extensions of Wright Medical Techn... , ,The distal femur consists of a rotating hinge ...
The MOST Options System is designed to enable patients facing severe bone loss of the knee or hip to regain use of their limbs and provides the potential for restoration of function. , ,The system go
...System (OSS) from Biomet Inc. offers the most comp... specifically for orthopaedic surgeons and oncolog...ir patients: significant bone loss, ligamentous de...throplasties, and multiple hip revision arthroplas...
Medicine Products: